Clindamycin phosphate 1.2% / Adapalene 0.15% / Benzoyl peroxide 3.1% Therapeutic Cheat Sheet
Cabtreo is the first FDA-approved fixed-dose triple-combination topical treatment for acne vulgaris, pairing a lincosamide antibiotic (clindamycin), a synthetic retinoid (adapalene), and a keratolytic oxidizing agent (benzoyl peroxide) into a single once-daily gel. This formulation targets several pillars of acne pathogenesis simultaneously: cutaneous C. acnes proliferation, abnormal keratinizatio …
Cabtreo is the first FDA-approved fixed-dose triple-combination topical treatment for acne vulgaris, pairing a lincosamide antibiotic (clindamycin), a synthetic retinoid (adapalene), and a keratolytic oxidizing agent (benzoyl peroxide) into a single once-daily gel. This formulation targets several pillars of acne pathogenesis simultaneously: cutaneous C. acnes proliferation, abnormal keratinizatio … 
The 2023 Skin of Color Update in New York City featured a comprehensive discussion on the evolving landscape of treating acne, with a particular focus on medical and procedural approaches. Attendees had the unique opportunity to hear Dr. Valerie Callendar, professor of dermatology at Howard University College of Medicine in Washington, DC, and Dr. Andrew Alexis, Professor of Clinical Dermatology … 
Straight from the desk of ODAC Medical Director, Dr. Adam Friedman, we share what’s popping in acne (spoiler alert: quite a lot!). According to Dr. Friedman, the innovation drought is over! Watch as he reviews all new topical and oral therapeutics (some of which are completely new active agents) and while at it, shares and debunks important information related to the management of acne vulgaris … 
Acne is the most common skin condition in the United States. Although it affects almost 50 million individuals annually, how it affects each person varies. Many epidemiologic studies have shown that acne is the most common presenting complaint in patients with Fitzpatrick skin types IV-VI. However, post-inflammatory hyperpigmentation is a common sequela of acne in patients of skin of color and a p … 
At the 17th Annual ODAC Dermatology, Aesthetic & Surgical Conference held in Orlando, Florida, Dr. Linda Stein Gold, Director of Dermatology Clinical Research and Division Head of Dermatology for the Henry Ford Health System, lectured on new and future treatments for acne. She opened her lecture by describing the traditional view of lesion progression in acne vulgaris, where the microcomedone …